Numerous
[용어속성] Term
Proteomics in the COVID-19 Battlefield: First Semester Check-Up
COVID-19 전장에서의 단백질체학: 첫 학기 검진
Review
[키워드] antiviral drug
antiviral drugs
biological system
biological systems
cellular
complex
Consequences
COVID-19
diagnosed
granularity
Health
heterogeneity
Host
interactions
knowledge
mass spectrometry
methodology
molecular
myriad
Numerous
occur
offer
pandemic
post-translational modification
post-translational modifications
predicted
Protein
proteomics
researcher
respiratory
SARS-CoV-2
SARS-CoV-2 virus
severe respiratory syndrome
severity
target
the disease
the SARS-CoV-2 virus
Viral
Viral particles
virus
with COVID-19
[DOI] 10.1002/pmic.202000198 PMC 바로가기 [Article Type] Review
[DOI] 10.1002/pmic.202000198 PMC 바로가기 [Article Type] Review
COVID-19 and Cancer Comorbidity: Therapeutic Opportunities and Challenges
COVID-19와 암 동반질환: 치료의 기회와 도전
Review
[키워드] acute respiratory syndrome
acute respiratory syndrome coronavirus
acute respiratory syndrome coronavirus 2
Affect
age
anticancer
approach
Cancer
cancer patient
Cancer patients
Care
caused
challenge
choice
Comorbidity
confirmed cases
coronavirus
coronavirus disease
Coronavirus disease 2019
Coronaviruses
cough
COVID-19
COVID-19 outbreak
COVID-19 pandemic
death
disease
disease severity
Genome
globe
higher risk
hospital
Human
Immunity
individual
infected individuals
Infection
Inflammation
multidisciplinary approach
Numerous
opportunity
pandemic
pathophysiology
Pathways
produced
reported
Repurposed drug
Repurposed drugs
respiratory
respiratory droplet
Respiratory droplets
Respiratory system
risk
SARS-CoV-2
SARS-CoV-2 pandemic
signaling pathway
sneezes
Spread
the SARS-CoV-2
treating COVID-19
Treatment
viral disease
Wuhan
Wuhan, China
[DOI] 10.7150/thno.51471 PMC 바로가기 [Article Type] Review
[DOI] 10.7150/thno.51471 PMC 바로가기 [Article Type] Review
Targeting the NO-cGMP-PDE5 pathway in COVID-19 infection. The DEDALO project
COVID-19 감염에서 NO-cGMP-PDE5 경로를 표적으로 합니다. 데달로 프로젝트
Article
[키워드] acting
activated T cells
administration
alveolar
ANG-II
anti-inflammatory response
biological drug
biological drugs
cause
Cell
cGMP
clinical trial
clotting
Complication
complications of COVID-19
contraindication
contraindications
COVID-19
COVID-19 disease
COVID-19 infection
cyclic GMP
cytokine
cytokine release
Cytokine storm
Cytokines
diabete
diabetes
Diabetes Mellitus
Diabetic
diffusion
disease
downregulation
drug
dysregulation
endothelial
Endothelial cell
endothelial cell damage
Evidence
expressed
favor
fibrosis
IL-6
immune system
implication
IMPROVE
infiltration
inhibiting
interstitial
interstitial pneumonia
limit
Liver function
low-grade inflammation
Lungs
material
men
mesenchymal cells
Metabolic diseases
modulating
monocyte
Necrosis
nitric oxide
Numerous
offer
ongoing trial
ongoing trials
outbreak
oxygen
pandemic
pathophysiology
pathway
Patient
patients with COVID-19
PDE5 inhibitor
PDE5 inhibitors
performed
positive
presenting
pro-inflammatory cytokines
pulmonary artery
pulmonary fibrosis
raise
reducing
renal impairment
resource
respiratory
respiratory infection
responsible
severe COVID-19 disease
Sildenafil
smooth muscle
smooth muscle cell
smooth muscle cells
stability
storm
switching
systematic review
systemic disease
T cells
targeting
temperature
thrombotic
Thrombotic complications
transition
type 2 diabete
Type 2 diabetes mellitus
Vascular
vessel
widespread
[DOI] 10.1111/andr.12837 PMC 바로가기 [Article Type] Article
[DOI] 10.1111/andr.12837 PMC 바로가기 [Article Type] Article
Bispecific VH/Fab antibodies targeting neutralizing and non-neutralizing Spike epitopes demonstrate enhanced potency against SARS-CoV-2
중화 및 비중화 스파이크 에피토프를 표적으로 하는 이중특이성 VH/Fab 항체는 SARS-CoV-2에 대해 강화된 효능을 보여줍니다
Article
[키워드] ACE2
Angiotensin-converting enzyme
antibodies
antibody
assist
binding
bispecific
COVID-19
domain
epitope
Fab
Fabs
IgG
IgGs
IMPROVE
knob-in-hole
neutralization
neutralize
Neutralizing
neutralizing antibody
non-neutralizing epitope
Numerous
RBD
reported
SARS-CoV-2
SARS-CoV-2 antibodies
spike
unique
virus
[DOI] 10.1080/19420862.2021.1893426 PMC 바로가기 [Article Type] Article
[DOI] 10.1080/19420862.2021.1893426 PMC 바로가기 [Article Type] Article
Understanding the genetic determinant of severity in viral diseases: a case of SARS-Cov-2 infection
Review
[키워드] Abstract
ACE2
Admission
Affect
age
Angiotensin-converting enzyme 2 (ACE2) gene
Asymptomatic
Clinical outcome
clinical response
clinical variability
co-morbidity
condition
contribute
coronavirus
COVID-19
Diagnosis
disease
disease severity
effort
Factor
Factors
Genetic
help
HLA
human gene
Human genetics
Human leucocyte antigen (HLA) allele
hypothetical
ICU
identify
in viral
increased risk
Infection
intensive care
life threatening
mild infection
Mutation
Numerous
occur
outbreak
outcome
pandemic
Patient
Prophylaxis
question
reported
Research
SARS-CoV-2
Severe infection
severity
shown
significantly
susceptibility
target
the disease
the SARS-CoV-2
therapy
TLR
TLR3
TLR7
Toll-like receptor (TLR)
understanding
unique
variant
Variation
viral infection
viral infections
[DOI] 10.1186/s43042-020-00122-z PMC 바로가기 [Article Type] Review
[DOI] 10.1186/s43042-020-00122-z PMC 바로가기 [Article Type] Review
A model to rate strategies for managing disease due to COVID-19 infection
Article
[키워드] alterations
approach
complex
correlated
COVID-19 infection
COVID-19 pandemic
disease
effective
Factor
fatality
Infection
infection rate
Local
machine
management
mathematical
measure
Numerous
pandemic
parameter
Perspective
professionals
reflected
reveal
SARS-CoV-2
Spread
Transmissibility
viral infection
Viral transmission
while
[DOI] 10.1038/s41598-020-79817-7 PMC 바로가기 [Article Type] Article
[DOI] 10.1038/s41598-020-79817-7 PMC 바로가기 [Article Type] Article
Early-pandemic wastewater surveillance of SARS-CoV-2 in Southern Nevada: Methodology, occurrence, and incidence/prevalence considerations
Full Paper
[키워드] Abstract
appear
approach
Community
comparability
Composite
Concentration
concentrations
conditions
COVID-19
detect
detection
driven by
early phase
Effect
epidemiological
exhibited
fecal
genetic marker
genetic material
global pandemic
highlighting
Image
incidence
increase in
infected individuals
measure
methodological
Mild
mitigate
multiple study
Numerous
Occurrence
pandemic
Prevalence
public health
quantification
ranged
reported
responsible
SARS-CoV-2
SARS-CoV-2 RNA
secondary
sensitivity
sewage
Surveillance
surveillance data
Variability
virus
Volume
wastewater surveillance
WHO
World Health Organization
[DOI] 10.1016/j.wroa.2020.100086 PMC 바로가기 [Article Type] Full Paper
[DOI] 10.1016/j.wroa.2020.100086 PMC 바로가기 [Article Type] Full Paper
Comparative efficacy and safety of pharmacological interventions for the treatment of COVID-19: A systematic review and network meta-analysis
COVID-19 치료를 위한 약리학적 중재의 비교 효능 및 안전성: 체계적인 검토 및 네트워크 메타 분석
Meta-Analysis
[키워드] 1.26
95% CI
95% confidence interval
Admission
aggravation
Alpha
Anakinra
analyses
Analysis
anti-inflammatory agent
anti-inflammatory agents
Asia
assessment
associations
Azithromycin
benefit
Cardiac complications
cardiac safety risk
cardiac safety risks
cardiac-impaired population
cardiac-impaired populations
carried
categories
category
Causality
certainty
clinical
clinical benefit
clinical benefits
Clinical outcome
clinical settings
clinical trial
ClinicalTrials
clinician
Cochrane Library
collected
Combination
Comparative
controlled trials
convalescent plasma
coronavirus disease
Coronavirus disease 2019
Corticosteroid
Corticosteroids
Course
COVID-19
COVID-19 disease
COVID-19 disease course
COVID-19 treatments
CRD42020186527
Critically ill
Critically ill patient
critically ill patients
daclatasvir
dataset
determine
development
disease course
drug
effective
Efficacy and safety
eligibility criteria
eligible
Europe
evaluate
Evidence
evidence of
fatal cardiac complication
fatal cardiac complications
Google Scholar
help
heterogeneous
High-dose
Hospitalization
hospitalized COVID-19 patients
Hydroxychloroquine
ICU
Immunoglobulin
information
intensive care
intensive care unit
interferon
interferon-alpha
Intravenous immunoglobulin
investigated
itolizumab
Ivermectin
IVIG
Level
management
mechanical ventilation
medRxiv
Meta-analysis
Middle East
mild patients
moderate
moderate to severe
moderate/high evidence certainty
Mortality
mortality rate
mortality rates
Network meta-analysis
NMA
non-ICU
non-ICU setting
noncardiac serious adverse events
North America
Numerous
observational studies
observational study
Odds ratio
outcome
Patient
patients hospitalized
pharmacological agent
pharmacological intervention
pharmacological interventions
pharmacological management
plasma
Policy
populations
Potential treatment
potential treatments
progression
PROSPERO
provide
QT prolongation
QT prolongation incidence
Randomized controlled trial
Randomized controlled trials
randomized trial
randomized trials
RCT
RCTs
recommendations
reduce
reduce COVID-19 aggravation
reduce mortality rate
reduced
reflected
registry
Remdesivir
Research
researcher
Result
risk
risk of bia
RoB
RoB2
ROBINS-I framework
searched
self-limiting disease
Serious Adverse Event
Serious Adverse Events
severe COVID-19 patient
severe disease
severe pneumonia
shown
significantly
sofosbuvir
sofosbuvir plus daclatasvir
South America
SSRN
standard care
Study protocol
supported
systematic review
systematic synthesis
Tocilizumab
translated
Treatment
treatment regimen
viral clearance rate
vulnerable population
WHO
WHO International Clinical Trials Registry Platform
[DOI] 10.1371/journal.pmed.1003501 PMC 바로가기 [Article Type] Meta-Analysis
[DOI] 10.1371/journal.pmed.1003501 PMC 바로가기 [Article Type] Meta-Analysis
Sex Differences in Reported Adverse Drug Reactions to COVID-19 Drugs in a Global Database of Individual Case Safety Reports
개별 사례 안전성 보고서의 글로벌 데이터베이스에서 보고된 COVID-19 약물에 대한 보고된 약물 부작용의 성별 차이
Article
[키워드] (azithromycin
abdominal pain
acute respiratory syndrome
acute respiratory syndrome coronavirus
ADR
ADRS
Adverse
Adverse drug reaction
Algorithm
Azithromycin
Chloroquine
clinical trial
Combination
coronavirus
coronavirus disease
Coronavirus disease 2019
COVID-19
COVID-19-specific treatment
COVID-19-specific treatments
database
diarrhoea
difference
drug
drug reaction
drugs
Effectiveness
electrocardiogram
evaluate
event
females
fixed
Frequency
Health Organization
Hepatitis
Hydroxychloroquine
identify
indication
indications
individual
International
investigated
Lopinavir
Lopinavir/ritonavir
male
males
nausea
Non-COVID-19
Numerous
Other
pandemic
pattern
performed
reaction
Remdesivir
remdesivir)
renal
report
reported
respiratory
review
Ritonavir
Safety
Sex
Sex difference
solidarity
the disease
therapeutic
Treatment
treatment of COVID-19
Trial
vomiting
World Health Organization
Wuhan
Wuhan, China
[DOI] 10.1007/s40264-020-01000-8 PMC 바로가기 [Article Type] Article
[DOI] 10.1007/s40264-020-01000-8 PMC 바로가기 [Article Type] Article